Orchard’s supply

Promising early data for a rare disease lentiviral gene therapy from Orchard Therapeutics Ltd. helped the Orphan disease company raise a $110 million series B round that it thinks will be enough to carry its lead program to commercial launch.

Baillie Gifford and ORI Capital led the round with participation from fellow new investors Temasek, Cowen Healthcare Investments, Juda Capital, Pavilion Capital, RTW Investments, Agent Capital and 4BIO Capital, as well as existing investors F-Prime Capital and UCL Technology Fund...